Miflasone (Beclometasone Dipropionate)

Beclometasone dipropionate binds to glucocorticoid receptors inside airway cells, altering gene transcription to suppress pro‑inflammatory cytokines and chemokines. This reduces inflammatory cell recruitment, edema, and mucus production, leading to decreased airway hyper‑responsiveness and improved airflow.

The appropriate dose of Miflasone is determined by the prescribing healthcare professional based on the severity of the patient’s asthma or COPD, age, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The pregnancy safety category for beclometasone dipropionate is not definitively established. Use during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their doctor.

To order Miflasone, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Miflasone contains beclometasone dipropionate, a well‑studied corticosteroid with a high topical potency and low systemic bioavailability when inhaled. Compared with agents such as budesonide or fluticasone, it offers similar anti‑inflammatory efficacy, but differences in particle size, device compatibility and dosing frequency may influence individual patient preference and adherence.

Miflasone should be stored at room temperature, below 25 °C, in its original packaging. Keep the inhaler away from direct sunlight, moisture and heat sources. Do not expose the device to freezing temperatures, and ensure the mouthpiece is clean before each use.

Miflasone is administered by inhalation using the supplied inhaler device. The patient should exhale fully, place the mouthpiece in the mouth, inhale steadily and deeply while actuating the device, then hold the breath for several seconds before exhaling. Rinsing the mouth after use helps reduce local side effects.

Serious risks include adrenal suppression, which can lead to reduced cortisol production, and paradoxical bronchospasm, a sudden worsening of airway obstruction after inhalation. Patients should also be alert for signs of pneumonia or severe allergic reactions and seek medical attention promptly if these occur.

Miflasone should be avoided in individuals with known hypersensitivity to beclometasone dipropionate or any component of the inhaler. It is also contraindicated in patients with active, untreated respiratory infections that could be worsened by corticosteroid therapy, unless the prescriber decides the benefits outweigh the risks.